- Police: Man dies from self-inflicted gunshot after standoff in south Cape (1/14/18)3
- Here's what's being built next to Chick-fil-A in Cape (1/18/18)1
- Author of Waller's manuscript rewarded for helping feds (1/13/18)
- Cape lands new summer-league baseball team; Capaha Field to see major upgrades (1/20/18)8
- Man sentenced to life for killing mother, burning her body; mouth taped shut at hearing (1/20/18)
- Poultry in motion: 4-H participants take first in nation with barbecue skills (1/13/18)1
- Redhawk Food Pantry helping Southeast students, employees who need assistance with food, supplies (1/19/18)2
- Word to your superintendent: Glass rocks Vanilla Ice parody to announce cancellation (1/13/18)3
- 3 mayor candidates in Scott City; former mayor Porch files for council seat (1/18/18)
- Chronic wasting disease found in 2 Southeast Missouri deer; whether disease transferable to humans unknown (1/18/18)
Experimental West Nile vaccine shows promise in lab monkeys
WASHINGTON -- A vaccine that combines key parts of two viruses has been shown to protect monkeys from West Nile virus, a mosquito-borne illness that has killed 10 Americans this year.
Scientists at the National Institute of Allergy and Infectious Diseases, or NIAID, one of the National Institutes of Health, made the vaccine by placing West Nile virus proteins into a modified virus that causes dengue fever. This created a live but weakened virus.
When injected into monkeys, the hybrid virus protected the animals from injected doses of West Nile virus. The researchers said the combined viruses crippled the West Nile virus but still caused a strong immune response against it.
In a laboratory test, the researchers injected 12 monkeys with the combined virus vaccine and injected eight other monkeys with either the West Nile virus or the dengue virus.
Six weeks later, all 20 monkeys were injected with West Nile virus. The dozen that received the combined virus vaccine developed antibodies that successfully protected the animals from the West Nile virus.
Human clinical trials with the vaccine are to begin this year, said Dr. Brian Murphy, a researcher in NIAID's Laboratory of Infectious Diseases.
"We're optimistic that our engineered virus vaccine will provide long-term immunity to West Nile virus, but the human clinical trials will give us the definitive data," Murphy said in a statement.
West Nile is spread to people through the bite of an infected mosquito. Usually the disease produces only flu-like symptoms, but some patients develop an inflammation of the brain that can be lethal. The disease is most severe among the elderly.
On the Net: